Panacea Biotec gets acceptance for ANDA for Paclitaxel Protein Bound Particles by USFDA

30 Nov 2017 Evaluate

Panacea Biotec’s abbreviated new drug application (ANDA) submitted under section 505(j) of the Federal Food, Drug and Cosmetic Act (FD&C Act) for Paclitaxel Protein Bound Particles for injectable Suspension, 100mg/vial has been accepted for filing by the US Food and Drug Administration (FDA).

This product is the generic version of Abraxane, marketed for the treatment of Metastatic Breast Cancer, Non-Small Cell Lung Cancer and Adenocarcinoma of the Pancreas in the US market. The annual sale of Abraxane worldwide is approximately $973.4 million and approximately $633.8 million in the US.

The company has already commercialized this product in India and emerging markets like Sri Lanka, Turkey etc. under the trademark - PacliALL. The company looks forward to commercializing this product in US and several other markets worldwide in collaboration with Apotex.

Panacea Biotec is a leading biotechnology company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and leading Biotechnology Companies in India.

Panacea Biotec Share Price

344.65 -0.10 (-0.03%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×